On 3 June 2009, the ACCC commenced a review of the proposed acquisition of Wyeth Corp by Pfizer Inc. Pfizer and Wyeth are both global pharmaceutical companies that compete in a number of human and animal health markets in Australia. Wyeth conducts its animal health business under the name Fort Dodge.
The ACCC concluded that the proposed acquisition would likely result in the substantial lessening of competition in a number of animal health markets. To address these competition concerns, Pfizer offered a court enforceable undertaking that will see Pfizer divest a variety of Fort Dodge assets.
The ACCC concluded that the proposed acquisition was unlikely to result in a substantial lessening of competition in any human health markets.
On 30 September 2009 the ACCC accepted the 87B undertaking offered by Pfizer and announced that it would not oppose the proposed acquisition.
Outcome of assessment
Not opposed subject to undertakings
Total review days *
49
Commenced public review
3rd June 2009
Date completed
30th September 2009
Market definition
Please refer to the Public Competition Assessment.
Competition analysis
Please refer to the Public Competition Assessment.
Public competition assessment
Public Competition Assessment 18th November 2009 D09+185734.pdf (172.5 KB)
Undertakings
Final 87B Undertakings 30th September 2009 D09+167487.pdf (2.4 MB)
